STUDY OBJECTIVE: We sought to compare the rate of @entity2146 after administration of intravenous @entity6916 as a 2-minute bolus or 15-minute infusion. METHODS: We conducted a prospective, randomized, double-blind study in the emergency department of a central-city teaching hospital. @entity1 aged 18 years or older treated with @entity6916 for @entity10 , @entity390 , or @entity391 were eligible for inclusion. Study @entity1 were randomized to receive 10 mg of @entity6916 administered intravenously by means of 2-minute push (bolus group) or 10 mg diluted in 50 mL of normal saline solution administered by means of intravenous infusion during a 15-minute period (infusion group). The main outcome was the number of study @entity1 experiencing @entity2146 within 60 minutes of administration. Akathisia was defined as either a spontaneous report of @entity2146 or @entity2146 or a change of 2 or more in the @entity1 -reported @entity2146 rating scale and a change of at least 1 in the investigator-observed @entity2146 rating scale. The intensity of @entity10 and @entity390 was measured with a 100-mm visual analog scale. RESULTS: One hundred @entity1 were enrolled. One study @entity1 was excluded after protocol violation. Seventy-three percent (73/99) of the study @entity1 were treated for @entity10 and 70% (70/99) for @entity390 . In the bolus group, 26.0% (13/50) had @entity2146 compared with 32.7% (16/49) in the infusion group (Delta=-6.7%; 95% confidence interval [CI] -24.6% to 11.2%). The difference between the bolus and infusion groups in the percentage of @entity1 who saw a 50% reduction in their @entity10 intensity within 30 minutes was 11.8% (95% CI -9.6% to 33.3%). The difference in the percentage of @entity1 with a 50% reduction in their @entity390 was 12.6% (95% CI -4.6% to 29.8%). CONCLUSION: A 50% reduction in the incidence of @entity2146 when @entity6916 was administered by means of 15-minute intravenous infusion versus a 2-minute intravenous push was not detected. The efficacy of @entity6916 in the treatment of @entity10 and @entity390 likewise did not appear to be affected by the rate of administration, although no formal statistical comparisons were made.

Intravenous administration of XXXX by 15-minute infusion versus 2-minute bolus does not affect the incidence of @entity2146 : a prospective, randomized, controlled trial.

@entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients', 'participant', 'patient'] @entity6916 :: ('MESH:D011346', 'Chemical') :: ['prochlorperazine'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity2146 :: ('MESH:D011595', 'Disease') :: ['restlessness', 'akathisia', 'agitation'] @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']
@entity6916 :: (MESH:D011346,Chemical) :: ['prochlorperazine']
